Politics and Legality
The Dales Report
2023-06-23
FDA Releases Much-Anticipated Draft Guidance On Psychedelic Research For Mental Health Conditions
The FDA)has released draft guidance aimed at researchers exploring the potential of psychedelic drugs for treating medical conditions
Share:
Related News
Live and Awake in LA
Having attended the surprisingly few SoCal events over the past few years, it was such a welcome pleasure to see familiar faces coming together in LA for 3 days of meaningful conversations centered around healing, community, access, learning, and networking at Psychedelic Awakening 2025 hosted by Psychedelic Institute of Los Angeles.
Read More
DEA Calls For Increased Production Of Some Psychedelics For Research, As Marijuana Quotas Level Out Ahead Of Scheduling Decision
The Drug Enforcement Administration (DEA) has released new quotas for the production of Schedule I and Schedule II controlled substances for research purposes—calling for an increase in the manufacturing of the psychedelics ibogaine, psilocybin and psilocyn, while continuing to maintain stable quotas for other substances such as marijuana, THC and MDMA. As DEA prepares to […]
Read More
Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming “No” Vote
Following last week’s negative headlines, we review how Lykos Therapeutics unsuccessfully sought to reassure the committee, how its apparent policy of minimal engagement might have backfired…
Read More
Australian Federal Government Funds Trial of MDMA-Assisted Therapy for Individuals Affected by Northern River Floods
Researchers at Southern Cross University (SCU) in Australia will trial the use of MDMA-assisted therapy (MDMA-AT) in patients suffering from natural disaster-related PTSD. The government has assigned…
Read More